Catalyst Pharmaceuticals Inc (CPRX)

🌿 Epilepsy: Cannabis vs. Synthetic Seizure Drugs
Medical cannabis: CBD oils and extracts are marketed as plant-based, holistic options. Families often see them as “natural relief” without the chemical baggage of traditional drugs.

Biotech/Pharma: Companies develop lab-engineered anti-seizure medications, often with complex side-effect profiles. Some pharma firms are even creating synthetic cannabinoids to patent and control.

The clash: Cannabis appeals to patients seeking authenticity and fewer side effects, while pharma emphasizes precision dosing and regulatory approval. $CPRX

🤩

CPRX...$17.22...🥳...https://www.globenewswire.com/news-release/2024/08/07/2926391/13009/en/Catalyst-Pharmaceuticals-Reports-Strong-Second-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html

The core mission of the Catalyst development program is to advance the treatment landscape for patients with rare, debilitating neuromuscular and neurological diseases.
June 5 3:30p Jefferies Global Healthcare Conference

New CPRX CEO Richard Daly is interviewed by IBD at investors.com. Pipeline discussion includes 3 rare disease, orphan drugs—Firdapse for treatment of neuromuscular conditions in small cell lung cancer patients, Fycompa for epilepsy and newly licensed Agamree with an NDA filed by partner Santhera for Duchenne muscular dystrophy.

Daly has previous experience with ABT, BMY, AZN, Takeda and 9 years on BOD of CPRX.

We hold 17k shares of CPRX in 2 portfolios.

Actually went to $22 retraced to $11 range...Now $17 range...🥳

CPRX over $10

FDA approval Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals

Source: GlobeNewswire Inc.

Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today reported that Santhera Pharmaceuticals ("Santhera") has obtained U.S. Food and Drug Administration ("FDA") approval for AGAMREE® (vamorolone) oral suspension 40 mg/mL for use in treating Duchenne Muscular Dystrophy ("DMD") in patients aged two years and older. AGAMREE offers a novel corticosteroid treatment option for DMD, addressing a significant unmet medical need. In July 2023, Catalyst secured the exclusive North American license and commercial rights for AGAMREE from Santhera for DMD and other potential indications, bolstering its neuroscience commercial portfolio with a highly synergistic neuromuscular asset. As part of that transaction, Santhera will promptly transfer the approved New Drug Application for AGAMREE to Catalyst.
FDA’s approval of AGAMREE® was based on the data from the pivotal Phase 2b VISION-DMD study as supplemented with safety information collected from three open-label studies, including extension studies. In these trials, AGAMREE was administered at doses ranging from 2 to 6 mg/kg/day, extending for a period of up to 48 months. Compared with current standard-of-care corticosteroids, this novel corticosteroid treatment exhibited comparable efficacy, with data suggesting a reduction in adverse events, notably related to bone health, growth trajectory, and behavior.

“We strongly believe that this novel steroid has the transformational potential to make a significant difference for patients living with Duchenne Muscular Dystrophy and potentially other chronic inflammatory diseases. The approval of AGAMREE underscores the potential of reshaping the DMD treatment paradigm for this life-threatening rare disease. The addition of AGAMREE expands our rare neuromuscular disease portfolio, and we look forward to executing on our proven commercial capabilities to bolster our long-term growth potential,” said Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals. “Our unwavering commitment extends beyond this important milestone as we are resolute in our mission to ensure that DMD patients in the U.S. have access to this treatment option as we believe that AGAMREE may offer the potential of increasing the duration of ambulation and mobility in these patients, thereby significantly improving their overall quality of life. We expect to launch the product in the first quarter of 2024. At that time, we will introduce a comprehensive financial assistance program aimed at helping ensure accessibility and minimizing patient co-pays and deductibles, thereby enhancing affordability for all DMD patients. We look forward to successfully commercializing this product with a continued commitment to serving our patient communities."

Upon the transfer of AGAMREE's NDA into its neuromuscular franchise, Catalyst will harness its product portfolio synergies by leveraging its well-established expertise and proven commercial capabilities. The Company plans to launch the product in Q1 2024, spearheaded by its seasoned and experienced U.S. commercial and medical affairs neuromuscular teams.

AGAMREE was granted Orphan Drug and Rare Pediatric Disease designations status for DMD in the U.S. and will be eligible for seven years of orphan drug exclusivity upon approval date and has issued pending patents that could provide protection until 2040.

CPRX...$6.95s clearing here on the Upper Bollie Breakout...:party:
[11:33 AM]
georgie18 — 11/02/2021
CPRX...$6.17...Psar flipped Bullish...MACD ready to Cross Positive...Money Flow/Aroon both suggest a strong Upside move...Break/hold $7.67 sets all time highs and Blue Skies territory with NO Upside Resistance...imo...we shall see... https://schrts.co/xkZTZjMN ...:party:

CPRX...$6.45...Pushing the Upper Band here...:party:
[9:03 AM]
georgie18 — 09/24/2021
CPRX...$5.05..Loading this on the add here...Psar flipped Bullish...watch for a Double Top Break/Hold in the $6.30 range...:party:

CPRX...$6.17...Psar flipped Bullish...MACD ready to Cross Positive...Money Flow/Aroon both suggest a strong Upside move...Break/hold $7.67 seta all time highs and Blue Skies territory with NO Upside Resistance...imo...we shall see... :party:https://schrts.co/xkZTZjMN ...

[7:51 AM]
georgie18 — 10/28/2021
CPRX...$5.87...Back in here on the Bullish Pole N Flag Reversal Pattern to the Upside off the 100ma support...imo...we shall see...:party:

CPRX...$6.10...Psar flipped Bullish ...:party:
[10:23 AM]
georgie18 — 10/28/2021
CPRX...$5.87...Back in here on the Bullish Pole N Flag Reversal Pattern to the Upside off the 100ma support...imo...we shall see...:party:

With Lawsuit WIN, let's get Bought by BP

I like 11.00 for that.

CPRX...$6.42...Breaking the Double top here...If she holds then $7 plus is coming...imo...we shall see...:party:
[11:35 AM]
georgie18 — 09/24/2021
CPRX...$5.05..Loading this on the add here...Psar flipped Bullish...watch for a Double Top Break/Hold in the $6.30 range...:party:

CPRX...$5.77s clearing here...on the Upper Bollie Break...off the $5.05 range alert...:party:

georgie18 — Today at 10:05 AM
georgie18 — 09/24/2021
CPRX...$5.05..Loading this on the add here...Psar flipped Bullish...watch for a Double Top Break/Hold in the $6.30 range...:party:

https://media.ca11.uscourts.gov/opinions/pub/files/202013922.pdf

CPRX wins its Orphan Drug case in the 11th Circuit Court of Appeals.

CPRX...$5.05..Loading this on the add here...Psar flipped Bullish...watch for a Double Top Break/Hold in the $6.30 range...
[7:59 AM]
georgie18 — 09/09/2021
CPRX...$5.18...Back in here on the Bullish Piercing Line Reversal Candle...Break/Hold $7.67 and its a Blue Skies Chart with NO Topside Resistance...imo...we shall see...

CPRX...$6.05...Beauty move on the CnH Breakout....Looking for a Blue Skies Breakout on the Double Top Break/Hold in the $7.60 range...No Topside Resistance if we get that Double Top Breakout...

Took some profit in the $5.50 range...back in
looking for the $10 range...imo...we shall see...

georgie18 — 03/01/2021
CPRX...$3.89...Cup N Handle Continuation Pattern setting up here...Handle needs to Break/Hold the $5 range for confirmation...imo...we shall see...

Chart...https://schrts.co/BkZsqTNi

CPRX...$5.09s clearing here...

CPRX...$4.94...Psar flipped to a Bullish buy Position...:partying_face:

CPRX...$4.37...CORAL GABLES, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that its Board of Directors has authorized the repurchase of up to $40 million of shares of Catalyst's outstanding common stock.

georgie18 Monday, 03/01/21 05:56:40 AM
Re: None 0
Post #
4106
of 4108
CPRX...$3.89...Cup N Handle Continuation Pattern setting up here...Handle needs to Break/Hold the $5 range for confirmation...imo...we shall see...

Chart...https://schrts.co/BkZsqTNi

Nice article.

https://www.investopedia.com/investing/biotech-stocks/?utm_campaign=quote-yahoo&utm_source=yahoo&utm_medium=referral

CPRX...$3.89...Cup N Handle Continuation Pattern setting up here...Handle needs to Break/Hold the $5 range for confirmation...imo...we shall see...

Chart...https://schrts.co/BkZsqTNi

I guess this board isn't active anymore...... To the MOON anyways

Volume before price, although quite a rise with this minimally higher volume.


36 mil float and 10% of outstanding short! Go CPRX

CPRX...$3.64...Psar flipped to a Bullish buy Position...:party:

CPRX...$3.69...in the P/M...

Feeling the Bern? CPRX ?

CPRX...$3.80...on the P/M gappa...
[7:07 AM]
georgie1811/04/2020
CPRX...$3.32...Psar flipped to a Bullish By Position...on volume...

CPRX...$3.52...

CPRX...$3.42...in the P/M...8K...https://www.otcmarkets.com/filing/html?id=14491440&guid=EvceUWsDF2zCrth

Q3-20 Financial Results
•
Product revenue, net in the third quarter of 2020 was $29.2 million, compared to $30.9 million for the third quarter of 2019.
•
Operating income for the third quarter of 2020 was $11.7 million, compared to $13.8 million in the third quarter of 2019.
•
Reported net income of $43.3 million, or $0.42 per basic and $0.41 per diluted share, in the third quarter of 2020, compared with net income of $13.6 million, or $0.13 per basic and diluted share, for the third quarter of 2019.
•
Net income in the third quarter of 2020 includes $31.3 million ($0.30 per basic and $0.29 per diluted share) of benefit from recording of deferred tax asset, upon reversal of valuation allowance.

News; $CPRX Small Cap Stocks Are Surging; 3 Penny Stocks To Buy Under $4

3 Penny Stocks To Buy For Under $4 Are you looking for small cap stocks right now? While many of these could be penny stocks , not all things defined as “small-cap” trade below $5 a share. In fact, the main focus when looking at any “cap stock” is the...

In case you are interested CPRX - Small Cap Stocks Are Surging; 3 Penny Stocks To Buy Under $4

CPRX...$3.32...Psar flipped to a Bullish By Position...on volume...

CPRX...$3.23...CORAL GABLES, Fla., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a new U.S. patent to Catalyst Pharmaceuticals for Firdapse® (amifampridine), U.S. Patent No. 10,793,893, Methods of Administering 3,4-Diaminopyridine, expiring April 7, 2034.

Judges decision really hurt this stock but what are adult patients choosing for their Rx. A generic compounded untested pill that needs to be refrigerated or the branded, better version, well studied Rx with the patient assistance program as well as coverage. Orphan Branded meds are important!! Follow the law on the books !!!

Florida District Court followed magistrate’s recommendation, granted summary judgment to FDA. CPRX will appeal that judgment to 11th Cir.

CPRX...$3.30s clearing here...

CPRX...$3.42...in the P/M...Psar flipped to a Bullish buy Position...

CPRX...$3.30...Bullish One White Soldier Reversal Pattern to the Upside...CPRX coming out of the Oversold Position as the Pincher Squeeze starts to diverge...

Psar flipped to a Bullish Buy Position...Macd Crossed positive...Been Accumulating in the $3/$5 range...Looking for a Blue Sky Breakout in the $7.50 range on the Break/Hold of a Long Term Double Top...imo...we shall see...

Chart...http://schrts.co/TsEyaYEd

Long Term Double Top Chart....http://schrts.co/cqbaYjwh

CPRX...$3.78...in the P/M...Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce Agreement to Make Firdapse® (amifampridine phosphate) Available to LEMS Patients in Canada...

https://www.otcmarkets.com/stock/CPRX/news/story?e&id=1672950

News: $CPRX 3 Stocks Robinhood Investors Love

Robinhood, a free app offering commission-free trading of stocks, options, and more, has attracted a lot of attention in recent months. Many investors who use it seem drawn to specific names, and they're not necessarily stocks that receive a lot of coverage. Among Robinhood's 100 most popular s...

Got this from CPRX - 3 Stocks Robinhood Investors Love

* * $CPRX Video Chart 08-12-2020 * *

Link to Video - click here to watch the technical chart video

CPRX...$3.87...in the P/M...CORAL GABLES, Fla., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 14/128,672. The allowed application, "Methods of Administering 3,4-Diaminopyridine", claims a method of treating a human patient diagnosed with a 3,4-DAP sensitive disease by administering 3,4-DAP (or salts thereof) to slow acetylating patients having certain mutations in each allele of the NAT2 gene.

https://www.otcmarkets.com/stock/CPRX/news/story?e&id=1667289

CPRX...$4.24...added here on the Reversal Candle off the Oversold Pincher Squeeze...

CPRX...$4.14...in the P/M...Bullish Harami Cross formed on the close as the Oversold Pincher starts to Squeeze here...adding in this range...

My $3.90 range shares looking better my $4.90 range shares not so good at the moment...averaging down on the pattern...

Chart...http://schrts.co/NZBaGirw

CPRX...$4.14...in the P/M...CORAL GABLES, Fla., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that Canada’s national healthcare regulatory agency, Health Canada, has approved the use of Firdapse® (amifampridine) for the treatment of patients in Canada with Lambert-Eaton myasthenic syndrome (LEMS), an ultra-rare, debilitating and potentially life-threatening neurodegenerative condition.

Does anyone have a link to the full text of the Florida magistrate’s recommendation to the District Court Judge? Tia.

CPRX...$4.32...in the A/H...
[4:10 PM]
georgie18Today at 10:01 AM
CPRX...$3.93...added here on the dip...not reading this one well at all...lets see what happens...

Orphan Drug Designations are in jeopardy with these “cancel culture” magistrate judges making poor decisions not based in practicing law standards. That’s my own opinion. If they want to change the laws and so forth that’s fine. But then I would change my behavior on investing my hard earned $s.